Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 A775_G776insYVMA PIK3CA R425L||lung non-small cell carcinoma||predicted - resistant||Trastuzumab||Case Reports/Case Series||Actionable||In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203).||28167203|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|